LPA(1) antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease with limited treatment options. A phase 2 trial (NCT01766817) showed that twice-daily treatment with BMS-986020, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, significantly decreased the slope of forced vital ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Decato, Benjamin E., Leeming, Diana Julie, Sand, Jannie Marie Bülow, Fischer, Aryeh, Du, Shuyan, Palmer, Scott M., Karsdal, Morten, Luo, Yi, Minnich, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933988/
https://www.ncbi.nlm.nih.gov/pubmed/35303880
http://dx.doi.org/10.1186/s12931-022-01980-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933988/
https://www.ncbi.nlm.nih.gov/pubmed/35303880
http://dx.doi.org/10.1186/s12931-022-01980-4

Ejemplares similares